You’d think that a move at the federal level in the U.S. to pardon marijuana possession offenses would help bring cannabis shares a lot closer to their fair value estimates, but even after Biden’s bump to the price of pot stocks, companies like Tilray TLRY are trading at a bargain.
While the market waits for the next steps toward U.S. federal legalization, it might be missing the continued growth potential at the international level. In its reverse merger with Tilray, legacy Aphria brought an extensive international distribution network, which should power roughly 15% average annual growth through 2030 in the global medicinal market, excluding the U.S. and Canada.
We still believe the U.S. offers the fastest growth potential of any market worldwide, and that’s where Tilray’s interest in MedMen pays off. Once legalization arrives, Tilray owns 21% of the U.S. multistate operator, and until then investors can focus on the positive adjusted earnings [EBITDA] that’s been running non-stop for 14 quarters now.
For Morningstar, I’m Andrew Willis.
Check out Morningstar.ca to watch "